14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 OTLK stock ended at $8.50. This is 1.16% less than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 5.44% from a day low at $8.45 to a day high of $8.91.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Sep 29, 2023 $0.218 $0.222 $0.215 $0.221 2 267 307
Sep 28, 2023 $0.214 $0.219 $0.214 $0.218 2 619 491
Sep 27, 2023 $0.214 $0.219 $0.212 $0.217 2 405 387
Sep 26, 2023 $0.215 $0.224 $0.214 $0.220 3 908 475
Sep 25, 2023 $0.213 $0.216 $0.210 $0.213 2 195 959
Sep 22, 2023 $0.208 $0.214 $0.205 $0.209 3 016 847
Sep 21, 2023 $0.215 $0.215 $0.209 $0.210 3 417 489
Sep 20, 2023 $0.225 $0.225 $0.212 $0.215 2 534 375
Sep 19, 2023 $0.213 $0.229 $0.210 $0.225 4 485 697
Sep 18, 2023 $0.220 $0.221 $0.211 $0.212 2 752 685
Sep 15, 2023 $0.226 $0.230 $0.215 $0.215 4 185 761
Sep 14, 2023 $0.238 $0.239 $0.220 $0.227 4 423 982
Sep 13, 2023 $0.241 $0.259 $0.228 $0.236 14 997 094
Sep 12, 2023 $0.220 $0.223 $0.211 $0.218 4 082 765
Sep 11, 2023 $0.211 $0.218 $0.209 $0.212 4 079 683
Sep 08, 2023 $0.215 $0.217 $0.200 $0.204 5 692 773
Sep 07, 2023 $0.220 $0.224 $0.215 $0.217 4 770 026
Sep 06, 2023 $0.228 $0.234 $0.220 $0.222 6 701 824
Sep 05, 2023 $0.220 $0.230 $0.215 $0.230 12 293 253
Sep 01, 2023 $0.233 $0.233 $0.211 $0.226 20 114 486
Aug 31, 2023 $0.254 $0.260 $0.226 $0.228 42 018 306
Aug 30, 2023 $0.279 $0.310 $0.210 $0.269 138 013 032
Aug 29, 2023 $1.29 $1.46 $1.19 $1.41 7 458 229
Aug 28, 2023 $1.25 $1.34 $1.19 $1.28 7 667 423
Aug 25, 2023 $1.18 $1.20 $1.14 $1.16 2 450 004
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT